Stephanie joined the HTS group in April 2016. She is responsible for developing and running high throughput screens, including ELISAs and various cellular phenotypic screens. Previously she performed cell-based assays as part of the Structural Genomic Consortium. She obtained her PhD from the University of North Carolina, Chapel Hill.
Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
Eyre DW. et al, (2021), Clin Microbiol Infect